FDA fast tracks Mesoblast COVID-19 treatment

FDA fast tracks Mesoblast COVID-19 treatment

A COVID-19 treatment being developed by Australian pharmaceutical company Mesoblast (ASX: MSB) has been granted Fast Track designation by the US Food and Drug Administration (FDA) today.

The designation is for MSB's treatment of acute respiratory distress syndrome (ARDs) - a potentially fatal complication of COVID-19 infection called remestemcel-L.

As a result, the FDA will assist in the development of remestemcel-L and will expedite the review of the drug because it fills an unmet medical need.

Under Fast Track designation, a Biologic License Application (BLA) for remestemcel-L is eligible for both rolling submission and priority review.

In its submission to the FDA Mesoblast highlighted results from a pilot study of remestemcel-L under emergency compassionate use at New York's Mt Sinai Hospital in March-April this year.

In this study, nine of 12 ventilator-dependent patients with moderate to severe COVID-19 ARDS were successfully discharged from hospital a median of 10 days after receiving two intravenous doses of remestemcel-L.

An ongoing Phase 3 trial of the drug in up to 300 ventilator-dependent patients is approximately two thirds enrolled.

Two interim analyses of this trial have been performed by the independent Data Safety Monitoring Board (DSMB), with recommendations to continue the trial.

Receipt of the Fast Track designation comes after Mesoblast entered into a license and collaboration agreement with Novartis for the development, manufacture and commercialisation of remestemcel-L.

As part of the deal Switzerland-based Novartis will make a US$50 million (AUD$68.7 million) upfront payment to Mesoblast.

Following the initiation of a Phase 3 clinical trial, Novartis will fully fund the global clinical development of the drug.

In addition, Mesoblast may receive a total of US$505 million (AUD$694 million) pending achievement of pre-commercialisation milestones for remestemcel-L and a further US$750 million (AUD$1 billion) based on achieving certain sales milestones.

Mesoblast will retain full rights for the use of remestemcel-L for treatment of graft versus host disease.

Updated at 9.58am AEDT on 2 December 2020.

Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support

How to conduct an effective board assessment: a step-by-step guide
Partner Content
Your directors should conduct a board assessment annually. Let's examine what a boa...
OnBoard
Advertisement

Related Stories

Rural veterinary group Apiam corrals NSW regional clinics for $11.2m

Rural veterinary group Apiam corrals NSW regional clinics for $11.2m

Rural veterinary clinic aggregator Apiam Animal Health (ASX: AHX) h...

Mighty Craft profitable as quarterly revenue nearly doubles

Mighty Craft profitable as quarterly revenue nearly doubles

A listed craft beverage business that owns 10 per cent of in-admini...

Will philosophy and ‘counterfactuals’ help us unlock the mysteries of AI?

Will philosophy and ‘counterfactuals’ help us unlock the mysteries of AI?

Artificial intelligence is increasingly being rolled out all around...

ACCC launches probe into misleading social media influencer posts

ACCC launches probe into misleading social media influencer posts

Australia's consumer watchdog is cracking down on social media ...